Adjust Font Size:

Press Releases

4/24/2014 Advanced Cell Technology's Chief Scientific Officer Dr. Robert Lanza

4/2/2014 Advanced Cell Technology to Host Conference Call to Provide a Corporate Update

3/24/2014 New Mesenchymal Stem Cell Population from Human Pluripotent Stem Cells Displays Potent Immunomodulatory and Therapeutic Properties

3/24/2014 ADVANCED CELL TECHNOLOGY TO PRESENT AT REGENENERATIVE MEDICINE INVESTOR DAY MARCH 26, 2014

1/22/2014 Advanced Cell Technology Announces Change in Management

12/18/2013 Advanced Cell Technology Announces Release of New Edition of Definitive Resource in Tissue Engineering

12/12/2013 Advanced Cell Technology Appoints Eddy Anglade M.D. Executive Vice President of Clinical Development

11/12/2013 Advanced Cell Technology Announces 2013 Third Quarter Results

11/11/2013 Advanced Cell Technology to Host Conference Call to Discuss 2013 Third Quarter Results and Provide a Corporate Update on Tuesday, November 12th

10/21/2013 ACT's Dr. Robert Lanza to Deliver Keynote Lecture at the World Conference on Regenerative Medicine

10/18/2013 Advanced Cell Technology to Webcast 2013 Annual Shareholders' Meeting on Tuesday, October 22nd

9/25/2013 Advanced Cell Technology to Present at 2013 Aegis Capital Healthcare Conference

9/24/2013 ACT’s Dr. Robert Lanza to Receive the Il Leone di San Marco Award in Medicine

9/19/2013 ACT Files Investigational New Animal Drug (INAD) Application with FDA to Treat 10 Different Disease Indications Using Pluripotent Stem Cells

8/12/2013 Advanced Cell Technology Files Preliminary Proxy Statement with Securities and Exchange Commission

8/7/2013 Advanced Cell Technology Announces Second Quarter 2013 Results

8/5/2013 Advanced Cell Technology to Host Conference Call to Discuss 2013 Second Quarter Results and Provide a Corporate Update on Wednesday, August 7th

7/17/2013 ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials

6/10/2013 ACT’s Dr. Robert Lanza to Deliver the Keynote Address at Brigham & Women’s Hospital Regenerative Medicine Center Inaugural Symposium

5/23/2013 ACT Appoints Edward Myles as Chief Financial Officer

5/16/2013 ACT Confirms Clinical Trial Participant Showed Improvement in Vision from 20/400 to 20/40 Following Treatment

5/10/2013 Advanced Cell Technology Announces 2013 First Quarter Results

5/6/2013 Advanced Cell Technology to Host Conference Call to Discuss 2013 First Quarter Results and Provide a Corporate Update on Thursday, May 9th

4/23/2013 ACT Initiates Higher-Dosage Patient Treatment in European Clinical Trial for Macular Degeneration

4/16/2013 Advanced Cell Technology to Present at Regen Med Investor Day 2013

4/15/2013 ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt's Macular Dystrophy

4/1/2013 ACT Initiates Treatment of Higher-Dosage Cohort in Clinical Trials for Dry Age-Related Macular Degeneration and Stargardt's Macular Dystrophy

3/22/2013 ACT’s Chief Scientific Officer Dr. Robert Lanza to Deliver the Nerem Lecture 2013 at the 17th Annual Hilton Head Workshop

3/14/2013 Advanced Cell Technology Receives Approval from Data Safety Monitoring Board (DSMB) to Initiate Treatment of Third Patient Cohort in All Three Clinical Trials

3/12/2013 ACT’s Dr. Robert Lanza Voted Top 4 “Most Influential People on Stem Cells”

3/8/2013 Advanced Cell Technology to Present at BIO-Europe Spring 2013

3/7/2013 Advanced Cell Technology Announces Fourth-Quarter and Year-end Results

3/4/2013 Advanced Cell Technology to Announce Fourth Quarter and Year-end Results on Thursday March 7th

2/11/2013 ACT’s Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief of BioResearch Open Access Journal

2/11/2013 ACT’s Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using the Company’s hESC-derived Cells to Treat Severe Myopia

2/8/2013 Advanced Cell Technology to Present at 15th Annual BIO CEO & Investor Conference

1/22/2013 Patients with Better Vision to be Enrolled in ACT's Clinical Trials for Macular Degeneration

1/17/2013 Advanced Cell Technology Announces Settlement of Litigation

1/8/2013 Advanced Cell Technology Achieves Clinical Milestone

1/7/2013 Advanced Cell Technology to Present at Biotech Showcase™ 2013

12/20/2012 New Scientist Magazine Selects ACT’s Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program As One of ‘10 Ideas That Will Shape The Year’

12/19/2012 Advanced Cell Technology Elects Not to Complete Reverse Split

12/17/2012 ACT Announces Completion of Higher-Dosage Cohort in European Clinical Trial for Stargardt’s Macular Dystrophy

12/3/2012 Advanced Cell Technology to Participate on Panels and Host Experts Luncheon at 2012 World Stem Cell Summit

11/28/2012 ACT Announces Completion of Higher-Dosage Cohort in Both U.S. Clinical Trials

11/8/2012 Advanced Cell Technology Announces Interim Data from Its Three Ongoing Macular Degeneration Trials

11/8/2012 Advanced Cell Technology Announces 2012 Third Quarter Results

11/5/2012 Advanced Cell Technology to Announce Third Quarter Financial Results on Thursday, November 8th

11/1/2012 ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Complete Second Patient Cohort in Clinical Trial for Dry AMD

10/26/2012 Advanced Cell Technology to Present at Stem Cell Meeting on the Mesa’s 2nd Annual Investor and Partnering Forum

10/22/2012 ACT’s European Clinical Trial Advances to First Patient Treatment with Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

10/18/2012 ACT Announces Second Stargardt’s Disease Patient Treated with Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

10/9/2012 ACT Announces Approval to Treat Additional Stargardt’s Disease Patients with Higher RPE Dosage in Both U.S. and European Clinical Trials

9/28/2012 New Edition of Definitive (Two-Volume) Resource in Stem Cells Released

9/20/2012 Advanced Cell Technology Secures New $35 Million Funding Commitment from Lincoln Park Capital

9/18/2012 ACT to Present at Terrapinn’s Stem Cells & Regenerative Medicine Congress in Boston

9/7/2012 Advanced Cell Technology to Present at 14th Annual Rodman & Renshaw Global Investment Conference

9/4/2012 ACT’s Chief Scientific Officer Dr. Robert Lanza to Deliver Opening Keynote Address at 4th Annual Stem Cell Symposium in Singapore

8/27/2012 ACT Comments on U.S. Appeals Court’s Dismissal Ruling in Case Challenging Federal Funding of Embryonic Stem Cell Research

8/20/2012 ACT Announces Scotland’s NHS Lothian as Additional Site for EU Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration

8/8/2012 Advanced Cell Technology Announces 2012 Second Quarter Results

8/2/2012 ACT Announces First Dry AMD Patient Treated with Higher Dosage of Embryonic Stem Cell-Derived RPE Cells

7/31/2012 Advanced Cell Technology to Announce Second Quarter Financial Results on Wednesday, August 8th

7/30/2012 ACT Treats 10th Patient in Embryonic Stem Cell Trials for Macular Degeneration

7/26/2012 ACT Issued Broad Patent for Human RPE Cells Derived From All Types of Pluripotent Stem Cells

7/12/2012 ACT Announces First Stargardt Patient Treated With Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

7/9/2012 ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD

7/2/2012 ACT Announces Second Patient with Stargardt's Disease Treated in EU Clinical Trial

6/14/2012 Advanced Cell Technology to Present at the 2012 Bio International Convention and the Clinical Outlooks for Regenerative Medicine Meeting

5/21/2012 Advanced Cell Technology to Present at World Stem Cells & Regenerative Medicine Congress in London

5/8/2012 Advanced Cell Technology Announces 2012 First Quarter Results

5/7/2012 Advanced Cell Technology to Host Conference Call to Discuss 2012 First Quarter Results and Provide Corporate Update on Wednesday, May 9th

5/2/2012 ACT Announces Massachusetts Eye and Ear as Additional Site for Clinical Trial for Dry Age-Related Macular Degeneration Using Human Embryonic Stem Cell-Derived RPE Cells

4/26/2012 Advanced Cell Technology Announces Webcast of Corporate Presentation at Annual Shareholders’ Meeting Today

4/24/2012 ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Increase RPE Dosage for Stargardt’s Disease Patients in U.S. Trial

4/20/2012 ACT Announces Third Dry AMD Patient Treated in Clinical Trial

4/16/2012 ACT Announces Second Patient with Dry AMD Treated in U.S. Clinical Trial with RPE Cells Derived from Embryonic Stem Cells

4/13/2012 Advanced Cell Technology to Webcast 2012 Annual Shareholders’ Meeting on April 26th

4/9/2012 ACT Appoints Michael Heffernan to Board of Directors

4/4/2012 ACT Announces Approval of Bascom Palmer Eye Institute as Additional Site for Stem Cell Clinical Trial for dry Age-Related Macular Degeneration

3/14/2012 ACT Announces Filing of Definitive Proxy

3/13/2012 Advanced Cell Technology to Present at the 24th Annual ROTH Conference

3/1/2012 Advanced Cell Technology Announces 2011 Financial Results

2/29/2012 Advanced Cell Technology To Announce 2011 Fourth Quarter and Year-End Results on March 1st

2/15/2012 ACT Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for Stargardt’s Disease

2/13/2012 ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from Embryonic Stem Cells

1/30/2012 ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration

1/25/2012 ACT Announces that Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation at UCLA’s Jules Stein Eye Institute

1/23/2012 ACT Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients

1/23/2012 ACT Announces Europe’s First Human Embryonic Stem Cell Transplant in Patient with Stargardt’s Disease

1/17/2012 Leading Eye Institute to Participate in ACT's Embryonic Stem Cell Clinical Trial for Macular Degeneration

1/9/2012 Advanced Cell Technology To Present in the Regenerative Medicine Insight Track at the Biotech Showcase™ 2012 in San Francisco

12/19/2011 Advanced Cell Technology Responds To Investor Inquiries

12/12/2011 ACT Announces Settlements and Filing of Preliminary Proxy

12/6/2011 ACT Announces Two New Appointments to Board of Directors

11/30/2011 Advanced Cell Technology to Present at 2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum

11/9/2011 Advanced Cell Technology Announces 2011 Third Quarter Results

11/7/2011 Advanced Cell Technology to Host Conference Call on Wednesday, November 9th to Discuss 2011 Third Quarter Results and Provide Update on Clinical Activities

10/18/2011 European Ruling May Not Impact Stem Cell Lines Derived Using Advanced Cell Technology's Single-Blastomere Method

10/5/2011 Scientific Luminary Dr. Robert Langer Joins ACT's Board of Directors

10/3/2011 ACT Chairman and CEO Gary Rabin to Present at World Stem Cell Summit

9/28/2011 ACT Receives Approval from Data and Safety Monitoring Board (DSMB) to Treat Next Patients in Stem Cell Clinical Trials

9/22/2011 ACT Receives Approval for First Human Embryonic Stem Cell Trial in Europe

9/19/2011 ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders

9/8/2011 Advanced Cell Technology to Present at Two Upcoming Conferences

8/8/2011 Advanced Cell Technology Announces 2011 Second Quarter Results

8/2/2011 Advanced Cell Technology to Host Conference Call to Discuss 2011 Second Quarter Results and Provide Corporate Update on Monday, Aug. 8

7/21/2011 ACT Obtains Exclusive License For Hemangioblast Technology In North America

7/14/2011 ACT Announces First Patients Undergo Embryonic Stem Cell Transplantation Treatment for Stargardt's Disease and Macular Degeneration at UCLA's Jules Stein Eye Institute

6/27/2011 ACT Granted EU Orphan Medicinal Product Designation for hESC-Derived RPE Cells for Treatment of Stargardt's Disease

6/21/2011 ACT and Roslin Cells Announce Collaboration for Storage and Distribution of Embryonic Stem Cells Using ACT's Blastomere Technology

6/16/2011 ACT Announces First Patients Enrolled in Two Clinical Trials Using Embryonic Stem Cells to Treat Stargardt's Disease and Dry Age-Related Macular Degeneration

6/3/2011 Advanced Cell Technology To Webcast 2011 Annual Stockholder's Meeting To be Held on Thursday, June 9th

5/16/2011 ACT Announces Oregon Health & Science University As Clinical Trial Site for its Phase 1/2 Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration

5/9/2011 Advanced Cell Technology Announces 2011 First Quarter Results

5/5/2011 ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells & Regenerative Medicine Congress in London

5/2/2011 Advanced Cell Technology Praises Federal Appeals Court Ruling Allowing for Continued Federal Funding of Embryonic Stem Cell Research

4/28/2011 ACT Announces UCLA Institutional Review Board (IRB) Approval of its Phase 1/2 Clinical Trials using hESC-Derived RPE Cells for the Treatment of Macular Degeneration

4/26/2011 ACT's Chief Scientific Officer Robert Lanza, M.D., to Deliver Speech at 3rd International Collaborative Symposium on Stem Cell Research in Seoul, South Korea

4/20/2011 ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration

3/23/2011 ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China

3/21/2011 Advanced Cell Technology Announces 2010 Results

3/17/2011 Advanced Cell Technology to Host Conference Call to Discuss 2010 Year-end Financial Results and Provide Corporate Update on Monday, March 21st

3/14/2011 ACT Interim Chairman and CEO Gary Rabin to Present at BIO-Europe Spring 2011 Conference

3/10/2011 ACT Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for hESC-Derived RPE Cells for Treatment of Stargardt’s Disease

3/9/2011 Advanced Cell Technology Comments on Recent Trading

2/23/2011 ACT Secures Patent to Generate Embryonic Stem Cells Without Embryo Destruction

1/12/2011 Advanced Cell Technology Interim Chairman and CEO Gary Rabin to Present at OneMedForum Finance Conference in San Francisco

1/11/2011 ACT’s Joint Venture SCRMI Reports in Prestigious Scientific Journal that Embryonic Stem Cells are a Potentially Unlimited Source of Functional Platelets for Transfusion

1/3/2011 Advanced Cell Technology Receives FDA Clearance For Clinical Trials Using Embryonic Stem Cells to Treat Age-Related Macular Degeneration

12/31/2010 Advanced Cell Technology Secures $25 Million Funding Commitment

12/27/2010 Advanced Cell Technology and The Roslin Institute Announce Agreement for Storage and Distribution of Embryonic Stem Cells Using ACT’s Blastomere Technology

12/14/2010 Advanced Cell Technology Mourns the Passing of its Chairman and CEO William M. Caldwell IV

12/2/2010 Advanced Cell Technology Strengthens Balance Sheet

11/22/2010 Advanced Cell Technology Receives FDA Clearance For the First Clinical Trial Using Embryonic Stem Cells to Treat Macular Degeneration

11/2/2010 Advanced Cell Technology Receives Federal Grant for Nearly $1 Million

10/14/2010 Advanced Cell Technology To Present Today at 18th Annual BioPartnering Europe Conference

9/22/2010 NIH Awards Dr. Robert Lanza of ACT and Dr. Kwang-Soo Kim of Harvard and McLean Hospital With Director’s Opportunity Award

9/10/2010 Advanced Cell Technology to Present at the 12th Annual Rodman & Renshaw Global Investment Conference

8/30/2010 Advanced Cell Technology’s Robust Cell Reprogramming/Transdifferentiation Platform Well Positioned To Capitalize on Emerging Trends in Regenerative Medicine

8/24/2010 ACT May Be Uniquely Positioned as One of Few Sources of ES cells That Could Qualify for Federal Funding Under Federal Court Ruling

8/16/2010 ACT Poised to Obtain and Control Key Patents to Generating iPS Cells

7/27/2010 ACT Files Documentation With FDA for Clinical Trials Using ES Cells to Treat Eye Disease

6/16/2010 Advanced Cell Technology Awarded Broad Patent For Production of Retinal Pigment Epithelial Cells

6/11/2010 NIH Approves Advanced Cell Technology's Stem Cell Line for Federal Funding

5/25/2010 Advanced Cell Technology to Present at the 11th Annual B. Riley & Co. Investor Conference in Santa Monica, California

5/12/2010 Advanced Cell Technology's CEO William M. Caldwell, IV to Present at Two European Healthcare Conferences

5/10/2010 Advanced Cell Technology’s Chief Scientific Officer Dr. Robert Lanza Honored By BioWorld Magazine As Leader Who Could Shape Biotech Over Next 20 Years

4/23/2010 Advanced Cell Technology’s Studies to Support Phase I Multicenter Trial of Patients with Stargardt’s Macular Dystrophy Demonstrate Excellent Safety Profile

4/5/2010 Advanced Cell Technology's Dr. Robert Lanza to Give Plenary, Keynote Address at the Translational Regenerative Medicine Forum

3/17/2010 Advanced Cell Technology Announces Year-End Results

3/10/2010 Advanced Cell Technology’s Chairman and CEO William M. Caldwell IV Interviewed on Bloomberg Radio’s Hays Advantage Show

3/2/2010 Advanced Cell Technology‘s RPE Cells Granted Orphan Drug Status from FDA for Treatment of Stargardt’s Macular Dystrophy

2/16/2010 Advanced Cell Technology's Research Featured in Scientific American, USA Today and Newsweek

2/11/2010 Advanced Cell and Colleagues Report Therapeutic Cells Derived From iPS Cells Display Early Aging

11/19/2009 Advanced Cell Technology Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells to Treat Eye Disease

9/22/2009 Advanced Cell Completing Pre-Clinical Activities in Preparation for IND Filing

9/21/2009 Dr. Robert Lanza Featured on Michio Kaku's 'Explorations in Science'

8/27/2009 Edmund Mickunas Named Vice President of Regulatory for Advanced Cell Technologies

8/27/2009 Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show

7/21/2009 Advanced Cell Technology Files 2009 First Quarter 10-Q To Become Current in Financial Statements

6/24/2009 Advanced Cell Technology and Collaborators at The Casey Eye Institute Present Promising Data Supporting Safety and Efficacy of Stem Cell Therapy to Combat Retinal Disease

5/20/2009 Advanced Cell Technology Provides Single Blastomere Technology To CHA Bio & Diostech Co., Ltd.

5/20/2009 Advanced Cell Technology Files Form 10-Q for its 2008 Second and Third Quarters

2/2/2009 Cloned Human Embryos Successfully Reprogrammed Using Human −But Not Animal− Eggs

1/5/2009 Functional Vasculature Generated From Advanced Cell Technologys Human Embryonic Stem Cells

12/30/2008 Joint Venture Between CHA Biotech and Advanced Cell Technology to be called Stem Cell & Regenerative Medicine International

12/18/2008 Advanced Cell Technology Licenses Non-Core Technology for $2.5 Million

12/17/2008 Advanced Cell Technologys Technology Platform Positioned To Receive Federal Funding

12/1/2008 Leading Korean Biotech Company & Advanced Cell Technology Form JV

11/17/2008 Advanced Cell Technology Comments on Technology Platform

8/30/2008 Advanced Cell Technology, Inc. Increases Funding Commitment to $1 Million

8/20/2008 Clinical-Scale Generation of Functional Red Blood Cells from Human Embryonic Stem Cells

4/10/2008 Advanced Cell Technology's Executive Invited to Present Today to FDA Advisory Committee on Cellular Tissue Therapies

4/3/2008 Advanced Cell Technology Platform Yields Over 140 Cell Types from Human Embryonic Stem Cells

4/2/2008 Barbara Walters' ABC Network Television Special Highlights Role that Advanced Cell Technology's Embryonic Stem Cells Play in Preventing Aging

4/1/2008 Advanced Cell Technology to be Featured Tonight on ABC Television's Special Report ''Live to 150, Can You Do It? Secrets to Living Longer''

3/12/2008 Advanced Cell Technology and Catholic Healthcare West Sign Clinical Agreement

3/5/2008 Advanced Cell Technology Announces Catheter Supply Agreement with Biologics Delivery Systems Group

2/29/2008 Advanced Cell Technology, Inc. Enters into License Agreement with Pharming Group N.V.

2/21/2008 Advanced Cell Technology Demonstrates Efficient Generation of Functional Hepatocytes (Liver cells) From Human Embryonic Stem Cells

2/11/2008 Advanced Cell Technology Announces Presentation of Results from Myoblast Study at ISCTR World Symposium

2/1/2008 Advanced Cell Technology Announces Completion of Pre-IND Meeting with the FDA for RPE Therapy for the Treatment of Retinal Degenerative Disease

1/10/2008 Advanced Cell Technology Announces Creation of Human Embryonic Stem Cell Lines Without the Destruction of Embryos

1/8/2008 Advanced Cell Technology Awarded Grant from the NIH

12/19/2007 Advanced Cell Technology Issues Letter to Investors

12/6/2007 Advanced Cell Technology Seeking International Partners for Its Therapeutic Programs

11/7/2007 Advanced Cell Technology Announces 12-Month Results of Myoblast Therapy Trial

11/7/2007 CHW Researcher Presents Results of ACT-Sponsored Trial Demonstrating Efficacy of ACT Myoblast Therapy for Heart Failure at AHA Meeting

11/6/2007 Advanced Cell Technology's Chief Scientific Officer Featured Speaker at American College of Rheumatology/ Association of Rheumatology Health Professionals

11/5/2007 Advanced Cell Technology and the Casey Eye Institute at Oregon Health & Science University Present Results of Functional Studies for RPE Program at Neuroscience 2007

11/2/2007 Advanced Cell Technology Announces Executive Promotions

11/1/2007 Advanced Cell Technology to Present at The Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th

10/31/2007 Advanced Cell Technology's Chief Scientific Officer Delivers Keynote Address at Leading International Stem Cell Conference

10/25/2007 Advanced Cell Presents Phase I (b) Data Demonstrating Safety and Optimal Dosage for Myoblast Program at TCT Conference and Exposition

10/16/2007 ACT's Myoblast Trial Selected as Late Breaking Trial for AHA Conference

10/11/2007 Advanced Cell Technology Announces the Promotion of Dr. Robert Lanza to Chief Scientific Officer

9/24/2007 Advanced Cell Technology Completes Acquisition of Mytogen, Inc.

9/20/2007 NIH Announces Advanced Cell Technology's 'Single Cell Embryo Biopsy Technique' as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding

9/4/2007 Advanced Cell Technology Completes $10 Million Private Placement

8/21/2007 Advanced Cell Technology’s Dr. Robert Lanza Makes List of ''100 Most Inspiring People in the Life-Sciences Industry''

8/2/2007 Advanced Cell Technology Enters Into Definitive Merger Agreement With Mytogen, Inc.

7/2/2007 Advanced Cell Technology Applauds Inclusion of Stem Cell Provision In $152 Billion Federal Funding Measure

6/28/2007 Registration Statement for Equity Related to Advanced Cell Technology’s September 2006 PIPE Becomes Effective

6/21/2007 Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo

6/21/2007 Advanced Cell Technology Announces Critical Advancements in its RPE Program for the Treatment of Macular Degeneration and Other Retinal Degenerative Diseases

6/13/2007 Advanced Cell Technology's VP of Research & Scientific Development, Dr. Robert Lanza, to Deliver Opening Keynote Address at Termis NA 2007 Conference on Regenerative Medicine

6/4/2007 Advanced Cell Technology to Host Conference Call and Webcast to Discuss Recent Developments and Planned Acquisition of Mytogen

5/31/2007 Advanced Cell Technology Enters Into Letter of Intent to Acquire Mytogen, Inc. and Proceed with the Human Clinical Trials Utilizing Myoblasts for the Treatment of Heart Failure

5/9/2007 Advanced Cell Technology’s CEO to Present at Rodman & Renshaw 4th Annual Global Healthcare Conference

5/9/2007 Advanced Cell Technology's Vice President of Research & Scientific Development to Present at the Life Science Institute's Symposium on Wednesday, May 9, 2007

5/7/2007 Precursor Cells Generated From Human Embryonic Stem Cells Show Ability to Repair Vascular Damage in Animals

5/2/2007 Advanced Cell Technology and Wisconsin Alumni Research Foundation Announce Commercial License Agreement

4/27/2007 Advanced Cell Technology’s General Counsel, Jonathan F. Atzen, Interviewed on Bloomberg Television

4/20/2007 Advanced Cell Technology’s Chairman and CEO, William M. Caldwell, IV, to Present at EQUITIES 56th Anniversary Spring Conference 2007

3/23/2007 Advanced Cell’s Michael D. West, Ph.D., To Speak at 3rd Annual Stem Cell Research and Therapeutics Summit on “Strategies for the Accelerated Development of Therapeutics from hES Cells”

3/20/2007 Advanced Cell Technology hESC lines to be used in CIRM-Funded Study To Test Development of New Therapies For Heart Disease

3/12/2007 Advanced Cell Technology Executives to Discuss “The Business of Stem Cells” and Participate in “Conversations with Experts” at The Stem Cell Meeting Hosted by Burrill and Company at UCSF

3/5/2007 Advanced Cell Technology’s Ability to Rescue Vision in Blind Rats Noted in Scientific American

2/28/2007 Advanced Cell Applauds $3 Billion Stem Cell Research Program, Proposition 71, Upheld Monday By A California Appeals Court

2/13/2007 Advanced Cell’s Michael West, Ph.D., Highlights ACTCellerate Platform, A Means of Accelerating the Differentiation of Cells from Human Embryonic Stem Cells, at 2nd Annual Stem Cell Summit

2/12/2007 Advanced Cell Technology Names Noted Biotech Industry Executive Dr. Pedro Huertas, as Chief Development Officer to Manage the Clinical Development and Regulatory Approval Process for its Stem Cell-Based Therapeutic Products

2/8/2007 Advanced Cell Technology Acquires Intellectual Property Assets of Infigen, Inc.

2/6/2007 Advanced Cell Technology Announces Collaboration with the Casey Eye Institute at Oregon Health and Science University

2/2/2007 Advanced Cell Technology Senior Scientist Dr. Robert Lanza Awarded for Outstanding Contributions to Biology by Brown University Biotech Group

1/23/2007 Advanced Cell Technology Engages Burrill & Company to Act as Financial Advisor to Accelerate Formation of New Strategic Partnerships

1/16/2007 Advanced Cell Technology Awarded Federal Grant from National Institutes of Health to Accelerate Embryonic Stem Cell Research

1/11/2007 Advanced Cell Technology CEO Interviewed On CNBC’s “Power Lunch”

1/5/2007 Advanced Cell Technology’s William Caldwell Interviewed By Bloomberg Television

12/14/2006 Advanced Cell Technology Invited to Deliver Keynote Address at Prestigious International Stem Cell Therapy and Regenerative Medicine Conference in London

12/11/2006 Advanced Cell Technology Executives to Present Keynote Address and Company Presentation at New York Society of Security Analysts (NYSSA) Conference

12/7/2006 Advanced Cell Technology’s Robert Lanza, M.D., to Deliver Keynote Address at the University of Florida’s Vision Research Symposium on December 7, 2006

11/9/2006 Advanced Cell Technology Names Current Chief Executive Officer William Caldwell as Chairman of the Board

11/7/2006 Advanced Cell Technology Scientist Dr. Robert Lanza Invited to Address The National Academy of Sciences at Stem Cell Policy Meeting

11/6/2006 Advanced Cell Technology to Present at the 2006 PIPES Conference on November 7th

11/6/2006 Advanced Cell Technology to Present Stem Cell Programs at Rodman & Renshaw’s Annual Healthcare Conference in New York

10/19/2006 Advanced Cell Technology To Present Progress Report on Product Development and ACTCellerate Platform at 2006 BIO Investor Forum

10/16/2006 Advanced Cell Technology’s Dr. Robert Lanza Will Be a Featured Speaker at the 6th Annual Stem Cells & Regenerative Medicine Meeting

9/21/2006 Advanced Cell Technology Reports Visual Function Rescue in Animals Utilizing Human Embryonic Stem Cell-Derived Retinal Cells

9/12/2006 WiCell Research Institute and Advanced Cell Technology Offer to Distribute New Stem Cell Lines to U.S. Researchers

9/6/2006 Advanced Cell Technology’s Dr. Robert Lanza Testifies Before U.S. Senate Subcommittee

9/6/2006 Chairman of Advanced Cell Technology’s Ethics Advisory Board Testifies Before U.S. Senate Subcommittee

9/6/2006 Advanced Cell Technology Announces Settlement of Patent Interference Action

8/23/2006 Advanced Cell Technology Announces Technique to Generate Human Embryonic Stem Cells that Maintains Developmental Potential of Embryo

8/22/2006 Advanced Cell Technology Announces Proposed Financing

7/25/2006 Advanced Cell Technology to Participate at the CIRM’s Roundtable Discussion on Industry & Stem Cells in California

7/21/2006 Advanced Cell Technology Applauds Governor Schwarzenegger for Directing $150 Million Loan to Fund Stem Cell Research

7/19/2006 Advanced Cell Technology Applauds Senate for Bipartisan Support of Stem Cell Legislation; Urges President Bush to fully support embryonic stem cell research

7/17/2006 Advanced Cell Technology Announces Support of Federal Stem Cell Legislation Favorable to the Field of Regenerative Medicine

7/11/2006 Dr. Robert Lanza of Advanced Cell Technology, Inc. and his colleagues receive praise for ''Essentials of Stem Cell Biology'' from The New England Journal of Medicine and Others

6/9/2006 Advanced Cell Technology to Participate at the Marcus Evans ''Facing Stem Cell Research Challenges'' Conference, June 8-9, 2006

6/6/2006 Advanced Cell Technology Unveils ACTCellerate Technology Platform at the European Stem Cells & Regenerative Medicine Congress 2006

5/15/2006 Advanced Cell Technology Announces IND Timetables for Key Therapeutic Programs

5/12/2006 Advanced Cell Technology Announces Cross License of Key Intellectual Property with Kirin

5/11/2006 Advanced Cell Technology to Present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference

5/8/2006 Advanced Cell Technology Announces Formation of Institutional Review Board and Commencement of SCNT Program

4/27/2006 Advanced Cell Technology Announces Collaboration with Xgene Corporation to Assess Its Dermal Cell Technologies in Human Skin Models

4/18/2006 Advanced Cell Technology Announces Completion of Its First GMP Laboratory

4/4/2006 Advanced Cell Technology Announces Exclusive License of Key Intellectual Property Portfolio on Somatic Cell Reprogramming Technology

3/10/2006 Advanced Cell Technology to Participate at The Stem Cell Meeting

3/6/2006 Advanced Cell Technology to Participate in the 1st International Conference on Cell Therapy and Regenerative Medicine

2/28/2006 Advanced Cell Technology Formally Moves Headquarters and Opens Research Facility in California

2/24/2006 Advanced Cell Technology to Participate in Medtech Insight Conference

2/22/2006 Crystal Research Associates, LLC Issues Executive Informational Overview® (EIO®) on Advanced Cell Technology

2/16/2006 Advanced Cell Technology to Participate in the Wharton Health Care Business Conference

2/10/2006 Advanced Cell Technology to Participate in the BIO CEO & Investor Conference 2006

2/9/2006 Leading Stem Cell Company Launches Research Facility in California

1/17/2006 Comprehensive New Book on Stem Cells Co-Edited by Advanced Cell Technology’s Dr. Robert Lanza

12/8/2005 Advanced Cell Technology to Present at the Harris Nesbitt Focus on Healthcare Conference on December 8th

11/23/2005 Scientists Allege U.S. Losing Lead in Stem Cell Research

11/21/2005 Advanced Cell Technology Appoints Two New Members to it's Board of Directors

11/8/2005 Robert Lanza, M.D., to Present at IBC Life Sciences’ Stem Cell Research Challenges Conference

11/7/2005 Advanced Cell Technology’s Chief Scientific Officer Michael West, Ph.D. to be Featured Guest Speaker at Rodman & Renshaw Techvest 7th Annual Healthcare Conference

10/27/2005 Executive Team of Advanced Cell Technology, Inc. to Present 
at the PIPEs Conference 2005 in New York

10/25/2005 Executive Team of Advanced Cell Technology, Inc. to Present at the C.E Unterberg Towbin Life Sciences Conference in New York

10/20/2005 Michael West, PhD, President and Chief Scientific Officer of Advanced Cell Technology, Inc. to Deliver Keynote Address at the University of Toronto’s “Challenges in Regenerative Medicine” Conference

10/16/2005 Advanced Cell Technology Announces Alternative Approach for Derivation
of Embryonic Stem Cell Lines

10/10/2005 C.E. Unterberg Towbin Conference Presentation

9/16/2005 Advanced Cell Technology Raises $17.75 Million through Private Placement of Convertible Notes and Warrants

9/9/2005 Advanced Cell Technology to Deliver the Keynote Address at the Strategies for Engineered Negligible Senescence (SENS) Conference

8/10/2005 Robert Lanza, M.D. to Deliver a Keynote Presentation at the Biotechniques Live! / Drug Discovery Technology & Development World Congress’ Annual Conference

8/5/2005 Advanced Cell Technology Announces New Board Member

7/27/2005 Advanced Cell Technology and The Burnham Institute Announce Collaboration to Isolate Stem Cell-Specific Differentiation Markers

7/12/2005 Dr. Robert Lanza of Advanced Cell Technology Testifies Before Senate Subcommittee

7/11/2005 Dr. Robert Lanza Of Advanced Cell Technology To Testify Before Senate Subcommittee

6/29/2005 Somatic Cell Nuclear Transfer Gives Old Animals Youthful Immune Cells

6/22/2005 A.C.T. Holdings, Inc. Announces Name Change to Advanced Cell Technology, Inc.

6/17/2005 Advanced Cell Technology Expands Senior Scientific Team into California

5/26/2005 Advanced Cell Technology Expands Senior Research Team

5/24/2005 Advanced Cell Technology Reports 2005 First Quarter Results and Highlights Intellectual Property Portfolio

5/19/2005 Advanced Cell Technology Expands Somatic Cell Nuclear Transfer (Cloning) and Cellular Reprogramming Intellectual Property Portfolio

5/4/2005 Michael West, PhD, to Deliver Keynote Address at UC Berkeley’sStem Cells in Regenerative Medicine Conference

4/20/2005 Advanced Cell Technology Names Jonathan F. Atzen as General Counsel

4/18/2005 Advanced Cell Technology Files 8-KA with Securities and Exchange Commission

4/11/2005 Michael West, PhD, to Deliver a Keynote Address at GTCbio Stem Cell Research & Therapeutics Conference

4/4/2005 James Stewart Named Chief Financial Officer at Advanced Cell Technology

3/22/2005 Dr. Robert Lanza of Advanced Cell Technology receives Wired Magazine’s 2005 Rave Award for Medicine

3/8/2005 First Derivation Of Human Embryonic Stem Cells Without Exposure To Cell Feeders

4/24/2014 Advanced Cell Technology's Chief Scientific Officer Dr. Robert Lanza

4/2/2014 Advanced Cell Technology to Host Conference Call to Provide a Corporate Update

3/24/2014 New Mesenchymal Stem Cell Population from Human Pluripotent Stem Cells Displays Potent Immunomodulatory and Therapeutic Properties

3/24/2014 ADVANCED CELL TECHNOLOGY TO PRESENT AT REGENENERATIVE MEDICINE INVESTOR DAY MARCH 26, 2014

1/22/2014 Advanced Cell Technology Announces Change in Management

12/18/2013 Advanced Cell Technology Announces Release of New Edition of Definitive Resource in Tissue Engineering

12/12/2013 Advanced Cell Technology Appoints Eddy Anglade M.D. Executive Vice President of Clinical Development

11/12/2013 Advanced Cell Technology Announces 2013 Third Quarter Results

11/11/2013 Advanced Cell Technology to Host Conference Call to Discuss 2013 Third Quarter Results and Provide a Corporate Update on Tuesday, November 12th

10/21/2013 ACT's Dr. Robert Lanza to Deliver Keynote Lecture at the World Conference on Regenerative Medicine

10/18/2013 Advanced Cell Technology to Webcast 2013 Annual Shareholders' Meeting on Tuesday, October 22nd

9/25/2013 Advanced Cell Technology to Present at 2013 Aegis Capital Healthcare Conference

9/24/2013 ACT’s Dr. Robert Lanza to Receive the Il Leone di San Marco Award in Medicine

9/19/2013 ACT Files Investigational New Animal Drug (INAD) Application with FDA to Treat 10 Different Disease Indications Using Pluripotent Stem Cells

8/12/2013 Advanced Cell Technology Files Preliminary Proxy Statement with Securities and Exchange Commission

8/7/2013 Advanced Cell Technology Announces Second Quarter 2013 Results

8/5/2013 Advanced Cell Technology to Host Conference Call to Discuss 2013 Second Quarter Results and Provide a Corporate Update on Wednesday, August 7th

7/17/2013 ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials

6/10/2013 ACT’s Dr. Robert Lanza to Deliver the Keynote Address at Brigham & Women’s Hospital Regenerative Medicine Center Inaugural Symposium

5/23/2013 ACT Appoints Edward Myles as Chief Financial Officer

5/16/2013 ACT Confirms Clinical Trial Participant Showed Improvement in Vision from 20/400 to 20/40 Following Treatment

5/10/2013 Advanced Cell Technology Announces 2013 First Quarter Results

5/6/2013 Advanced Cell Technology to Host Conference Call to Discuss 2013 First Quarter Results and Provide a Corporate Update on Thursday, May 9th

4/23/2013 ACT Initiates Higher-Dosage Patient Treatment in European Clinical Trial for Macular Degeneration

4/16/2013 Advanced Cell Technology to Present at Regen Med Investor Day 2013

4/15/2013 ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt's Macular Dystrophy

4/1/2013 ACT Initiates Treatment of Higher-Dosage Cohort in Clinical Trials for Dry Age-Related Macular Degeneration and Stargardt's Macular Dystrophy

3/22/2013 ACT’s Chief Scientific Officer Dr. Robert Lanza to Deliver the Nerem Lecture 2013 at the 17th Annual Hilton Head Workshop

3/14/2013 Advanced Cell Technology Receives Approval from Data Safety Monitoring Board (DSMB) to Initiate Treatment of Third Patient Cohort in All Three Clinical Trials

3/12/2013 ACT’s Dr. Robert Lanza Voted Top 4 “Most Influential People on Stem Cells”

3/8/2013 Advanced Cell Technology to Present at BIO-Europe Spring 2013

3/7/2013 Advanced Cell Technology Announces Fourth-Quarter and Year-end Results

3/4/2013 Advanced Cell Technology to Announce Fourth Quarter and Year-end Results on Thursday March 7th

2/11/2013 ACT’s Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief of BioResearch Open Access Journal

2/11/2013 ACT’s Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using the Company’s hESC-derived Cells to Treat Severe Myopia

2/8/2013 Advanced Cell Technology to Present at 15th Annual BIO CEO & Investor Conference

1/22/2013 Patients with Better Vision to be Enrolled in ACT's Clinical Trials for Macular Degeneration

1/17/2013 Advanced Cell Technology Announces Settlement of Litigation

1/8/2013 Advanced Cell Technology Achieves Clinical Milestone

1/7/2013 Advanced Cell Technology to Present at Biotech Showcase™ 2013

12/20/2012 New Scientist Magazine Selects ACT’s Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program As One of ‘10 Ideas That Will Shape The Year’

12/19/2012 Advanced Cell Technology Elects Not to Complete Reverse Split

12/17/2012 ACT Announces Completion of Higher-Dosage Cohort in European Clinical Trial for Stargardt’s Macular Dystrophy

12/3/2012 Advanced Cell Technology to Participate on Panels and Host Experts Luncheon at 2012 World Stem Cell Summit

11/28/2012 ACT Announces Completion of Higher-Dosage Cohort in Both U.S. Clinical Trials

11/8/2012 Advanced Cell Technology Announces Interim Data from Its Three Ongoing Macular Degeneration Trials

11/8/2012 Advanced Cell Technology Announces 2012 Third Quarter Results

11/5/2012 Advanced Cell Technology to Announce Third Quarter Financial Results on Thursday, November 8th

11/1/2012 ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Complete Second Patient Cohort in Clinical Trial for Dry AMD

10/26/2012 Advanced Cell Technology to Present at Stem Cell Meeting on the Mesa’s 2nd Annual Investor and Partnering Forum

10/22/2012 ACT’s European Clinical Trial Advances to First Patient Treatment with Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

10/18/2012 ACT Announces Second Stargardt’s Disease Patient Treated with Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

10/9/2012 ACT Announces Approval to Treat Additional Stargardt’s Disease Patients with Higher RPE Dosage in Both U.S. and European Clinical Trials

9/28/2012 New Edition of Definitive (Two-Volume) Resource in Stem Cells Released

9/20/2012 Advanced Cell Technology Secures New $35 Million Funding Commitment from Lincoln Park Capital

9/18/2012 ACT to Present at Terrapinn’s Stem Cells & Regenerative Medicine Congress in Boston

9/7/2012 Advanced Cell Technology to Present at 14th Annual Rodman & Renshaw Global Investment Conference

9/4/2012 ACT’s Chief Scientific Officer Dr. Robert Lanza to Deliver Opening Keynote Address at 4th Annual Stem Cell Symposium in Singapore

8/27/2012 ACT Comments on U.S. Appeals Court’s Dismissal Ruling in Case Challenging Federal Funding of Embryonic Stem Cell Research

8/20/2012 ACT Announces Scotland’s NHS Lothian as Additional Site for EU Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration

8/8/2012 Advanced Cell Technology Announces 2012 Second Quarter Results

8/2/2012 ACT Announces First Dry AMD Patient Treated with Higher Dosage of Embryonic Stem Cell-Derived RPE Cells

7/31/2012 Advanced Cell Technology to Announce Second Quarter Financial Results on Wednesday, August 8th

7/30/2012 ACT Treats 10th Patient in Embryonic Stem Cell Trials for Macular Degeneration

7/26/2012 ACT Issued Broad Patent for Human RPE Cells Derived From All Types of Pluripotent Stem Cells

7/12/2012 ACT Announces First Stargardt Patient Treated With Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

7/9/2012 ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD

7/2/2012 ACT Announces Second Patient with Stargardt's Disease Treated in EU Clinical Trial

6/14/2012 Advanced Cell Technology to Present at the 2012 Bio International Convention and the Clinical Outlooks for Regenerative Medicine Meeting

5/21/2012 Advanced Cell Technology to Present at World Stem Cells & Regenerative Medicine Congress in London

5/8/2012 Advanced Cell Technology Announces 2012 First Quarter Results

5/7/2012 Advanced Cell Technology to Host Conference Call to Discuss 2012 First Quarter Results and Provide Corporate Update on Wednesday, May 9th

5/2/2012 ACT Announces Massachusetts Eye and Ear as Additional Site for Clinical Trial for Dry Age-Related Macular Degeneration Using Human Embryonic Stem Cell-Derived RPE Cells

4/26/2012 Advanced Cell Technology Announces Webcast of Corporate Presentation at Annual Shareholders’ Meeting Today

4/24/2012 ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Increase RPE Dosage for Stargardt’s Disease Patients in U.S. Trial

4/20/2012 ACT Announces Third Dry AMD Patient Treated in Clinical Trial

4/16/2012 ACT Announces Second Patient with Dry AMD Treated in U.S. Clinical Trial with RPE Cells Derived from Embryonic Stem Cells

4/13/2012 Advanced Cell Technology to Webcast 2012 Annual Shareholders’ Meeting on April 26th

4/9/2012 ACT Appoints Michael Heffernan to Board of Directors

4/4/2012 ACT Announces Approval of Bascom Palmer Eye Institute as Additional Site for Stem Cell Clinical Trial for dry Age-Related Macular Degeneration

3/14/2012 ACT Announces Filing of Definitive Proxy

3/13/2012 Advanced Cell Technology to Present at the 24th Annual ROTH Conference

3/1/2012 Advanced Cell Technology Announces 2011 Financial Results

2/29/2012 Advanced Cell Technology To Announce 2011 Fourth Quarter and Year-End Results on March 1st

2/15/2012 ACT Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for Stargardt’s Disease

2/13/2012 ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from Embryonic Stem Cells

1/30/2012 ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration

1/25/2012 ACT Announces that Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation at UCLA’s Jules Stein Eye Institute

1/23/2012 ACT Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients

1/23/2012 ACT Announces Europe’s First Human Embryonic Stem Cell Transplant in Patient with Stargardt’s Disease

1/17/2012 Leading Eye Institute to Participate in ACT's Embryonic Stem Cell Clinical Trial for Macular Degeneration

1/9/2012 Advanced Cell Technology To Present in the Regenerative Medicine Insight Track at the Biotech Showcase™ 2012 in San Francisco

12/19/2011 Advanced Cell Technology Responds To Investor Inquiries

12/12/2011 ACT Announces Settlements and Filing of Preliminary Proxy

12/6/2011 ACT Announces Two New Appointments to Board of Directors

11/30/2011 Advanced Cell Technology to Present at 2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum

11/9/2011 Advanced Cell Technology Announces 2011 Third Quarter Results

11/7/2011 Advanced Cell Technology to Host Conference Call on Wednesday, November 9th to Discuss 2011 Third Quarter Results and Provide Update on Clinical Activities

10/18/2011 European Ruling May Not Impact Stem Cell Lines Derived Using Advanced Cell Technology's Single-Blastomere Method

10/5/2011 Scientific Luminary Dr. Robert Langer Joins ACT's Board of Directors

10/3/2011 ACT Chairman and CEO Gary Rabin to Present at World Stem Cell Summit

9/28/2011 ACT Receives Approval from Data and Safety Monitoring Board (DSMB) to Treat Next Patients in Stem Cell Clinical Trials

9/22/2011 ACT Receives Approval for First Human Embryonic Stem Cell Trial in Europe

9/19/2011 ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders

9/8/2011 Advanced Cell Technology to Present at Two Upcoming Conferences

8/8/2011 Advanced Cell Technology Announces 2011 Second Quarter Results

8/2/2011 Advanced Cell Technology to Host Conference Call to Discuss 2011 Second Quarter Results and Provide Corporate Update on Monday, Aug. 8

7/21/2011 ACT Obtains Exclusive License For Hemangioblast Technology In North America

7/14/2011 ACT Announces First Patients Undergo Embryonic Stem Cell Transplantation Treatment for Stargardt's Disease and Macular Degeneration at UCLA's Jules Stein Eye Institute

6/27/2011 ACT Granted EU Orphan Medicinal Product Designation for hESC-Derived RPE Cells for Treatment of Stargardt's Disease

6/21/2011 ACT and Roslin Cells Announce Collaboration for Storage and Distribution of Embryonic Stem Cells Using ACT's Blastomere Technology

6/16/2011 ACT Announces First Patients Enrolled in Two Clinical Trials Using Embryonic Stem Cells to Treat Stargardt's Disease and Dry Age-Related Macular Degeneration

6/3/2011 Advanced Cell Technology To Webcast 2011 Annual Stockholder's Meeting To be Held on Thursday, June 9th

5/16/2011 ACT Announces Oregon Health & Science University As Clinical Trial Site for its Phase 1/2 Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration

5/9/2011 Advanced Cell Technology Announces 2011 First Quarter Results

5/5/2011 ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells & Regenerative Medicine Congress in London

5/2/2011 Advanced Cell Technology Praises Federal Appeals Court Ruling Allowing for Continued Federal Funding of Embryonic Stem Cell Research

4/28/2011 ACT Announces UCLA Institutional Review Board (IRB) Approval of its Phase 1/2 Clinical Trials using hESC-Derived RPE Cells for the Treatment of Macular Degeneration

4/26/2011 ACT's Chief Scientific Officer Robert Lanza, M.D., to Deliver Speech at 3rd International Collaborative Symposium on Stem Cell Research in Seoul, South Korea

4/20/2011 ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration

3/23/2011 ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China

3/21/2011 Advanced Cell Technology Announces 2010 Results

3/17/2011 Advanced Cell Technology to Host Conference Call to Discuss 2010 Year-end Financial Results and Provide Corporate Update on Monday, March 21st

3/14/2011 ACT Interim Chairman and CEO Gary Rabin to Present at BIO-Europe Spring 2011 Conference

3/10/2011 ACT Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for hESC-Derived RPE Cells for Treatment of Stargardt’s Disease

3/9/2011 Advanced Cell Technology Comments on Recent Trading

2/23/2011 ACT Secures Patent to Generate Embryonic Stem Cells Without Embryo Destruction

1/12/2011 Advanced Cell Technology Interim Chairman and CEO Gary Rabin to Present at OneMedForum Finance Conference in San Francisco

1/11/2011 ACT’s Joint Venture SCRMI Reports in Prestigious Scientific Journal that Embryonic Stem Cells are a Potentially Unlimited Source of Functional Platelets for Transfusion

1/3/2011 Advanced Cell Technology Receives FDA Clearance For Clinical Trials Using Embryonic Stem Cells to Treat Age-Related Macular Degeneration

12/31/2010 Advanced Cell Technology Secures $25 Million Funding Commitment

12/27/2010 Advanced Cell Technology and The Roslin Institute Announce Agreement for Storage and Distribution of Embryonic Stem Cells Using ACT’s Blastomere Technology

12/14/2010 Advanced Cell Technology Mourns the Passing of its Chairman and CEO William M. Caldwell IV

12/2/2010 Advanced Cell Technology Strengthens Balance Sheet

11/22/2010 Advanced Cell Technology Receives FDA Clearance For the First Clinical Trial Using Embryonic Stem Cells to Treat Macular Degeneration

11/2/2010 Advanced Cell Technology Receives Federal Grant for Nearly $1 Million

10/14/2010 Advanced Cell Technology To Present Today at 18th Annual BioPartnering Europe Conference

9/22/2010 NIH Awards Dr. Robert Lanza of ACT and Dr. Kwang-Soo Kim of Harvard and McLean Hospital With Director’s Opportunity Award

9/10/2010 Advanced Cell Technology to Present at the 12th Annual Rodman & Renshaw Global Investment Conference

8/30/2010 Advanced Cell Technology’s Robust Cell Reprogramming/Transdifferentiation Platform Well Positioned To Capitalize on Emerging Trends in Regenerative Medicine

8/24/2010 ACT May Be Uniquely Positioned as One of Few Sources of ES cells That Could Qualify for Federal Funding Under Federal Court Ruling

8/16/2010 ACT Poised to Obtain and Control Key Patents to Generating iPS Cells

7/27/2010 ACT Files Documentation With FDA for Clinical Trials Using ES Cells to Treat Eye Disease

6/16/2010 Advanced Cell Technology Awarded Broad Patent For Production of Retinal Pigment Epithelial Cells

6/11/2010 NIH Approves Advanced Cell Technology's Stem Cell Line for Federal Funding

5/25/2010 Advanced Cell Technology to Present at the 11th Annual B. Riley & Co. Investor Conference in Santa Monica, California

5/12/2010 Advanced Cell Technology's CEO William M. Caldwell, IV to Present at Two European Healthcare Conferences

5/10/2010 Advanced Cell Technology’s Chief Scientific Officer Dr. Robert Lanza Honored By BioWorld Magazine As Leader Who Could Shape Biotech Over Next 20 Years

4/23/2010 Advanced Cell Technology’s Studies to Support Phase I Multicenter Trial of Patients with Stargardt’s Macular Dystrophy Demonstrate Excellent Safety Profile

4/5/2010 Advanced Cell Technology's Dr. Robert Lanza to Give Plenary, Keynote Address at the Translational Regenerative Medicine Forum

3/17/2010 Advanced Cell Technology Announces Year-End Results

3/10/2010 Advanced Cell Technology’s Chairman and CEO William M. Caldwell IV Interviewed on Bloomberg Radio’s Hays Advantage Show

3/2/2010 Advanced Cell Technology‘s RPE Cells Granted Orphan Drug Status from FDA for Treatment of Stargardt’s Macular Dystrophy

2/16/2010 Advanced Cell Technology's Research Featured in Scientific American, USA Today and Newsweek

2/11/2010 Advanced Cell and Colleagues Report Therapeutic Cells Derived From iPS Cells Display Early Aging

11/19/2009 Advanced Cell Technology Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells to Treat Eye Disease

9/22/2009 Advanced Cell Completing Pre-Clinical Activities in Preparation for IND Filing

9/21/2009 Dr. Robert Lanza Featured on Michio Kaku's 'Explorations in Science'

8/27/2009 Edmund Mickunas Named Vice President of Regulatory for Advanced Cell Technologies

8/27/2009 Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show

7/21/2009 Advanced Cell Technology Files 2009 First Quarter 10-Q To Become Current in Financial Statements

6/24/2009 Advanced Cell Technology and Collaborators at The Casey Eye Institute Present Promising Data Supporting Safety and Efficacy of Stem Cell Therapy to Combat Retinal Disease

5/20/2009 Advanced Cell Technology Provides Single Blastomere Technology To CHA Bio & Diostech Co., Ltd.

5/20/2009 Advanced Cell Technology Files Form 10-Q for its 2008 Second and Third Quarters

2/2/2009 Cloned Human Embryos Successfully Reprogrammed Using Human −But Not Animal− Eggs

1/5/2009 Functional Vasculature Generated From Advanced Cell Technologys Human Embryonic Stem Cells

12/30/2008 Joint Venture Between CHA Biotech and Advanced Cell Technology to be called Stem Cell & Regenerative Medicine International

12/18/2008 Advanced Cell Technology Licenses Non-Core Technology for $2.5 Million

12/17/2008 Advanced Cell Technologys Technology Platform Positioned To Receive Federal Funding

12/1/2008 Leading Korean Biotech Company & Advanced Cell Technology Form JV

11/17/2008 Advanced Cell Technology Comments on Technology Platform

8/30/2008 Advanced Cell Technology, Inc. Increases Funding Commitment to $1 Million

8/20/2008 Clinical-Scale Generation of Functional Red Blood Cells from Human Embryonic Stem Cells

4/10/2008 Advanced Cell Technology's Executive Invited to Present Today to FDA Advisory Committee on Cellular Tissue Therapies

4/3/2008 Advanced Cell Technology Platform Yields Over 140 Cell Types from Human Embryonic Stem Cells

4/2/2008 Barbara Walters' ABC Network Television Special Highlights Role that Advanced Cell Technology's Embryonic Stem Cells Play in Preventing Aging

4/1/2008 Advanced Cell Technology to be Featured Tonight on ABC Television's Special Report ''Live to 150, Can You Do It? Secrets to Living Longer''

3/12/2008 Advanced Cell Technology and Catholic Healthcare West Sign Clinical Agreement

3/5/2008 Advanced Cell Technology Announces Catheter Supply Agreement with Biologics Delivery Systems Group

2/29/2008 Advanced Cell Technology, Inc. Enters into License Agreement with Pharming Group N.V.

2/21/2008 Advanced Cell Technology Demonstrates Efficient Generation of Functional Hepatocytes (Liver cells) From Human Embryonic Stem Cells

2/11/2008 Advanced Cell Technology Announces Presentation of Results from Myoblast Study at ISCTR World Symposium

2/1/2008 Advanced Cell Technology Announces Completion of Pre-IND Meeting with the FDA for RPE Therapy for the Treatment of Retinal Degenerative Disease

1/10/2008 Advanced Cell Technology Announces Creation of Human Embryonic Stem Cell Lines Without the Destruction of Embryos

1/8/2008 Advanced Cell Technology Awarded Grant from the NIH

12/19/2007 Advanced Cell Technology Issues Letter to Investors

12/6/2007 Advanced Cell Technology Seeking International Partners for Its Therapeutic Programs

11/7/2007 Advanced Cell Technology Announces 12-Month Results of Myoblast Therapy Trial

11/7/2007 CHW Researcher Presents Results of ACT-Sponsored Trial Demonstrating Efficacy of ACT Myoblast Therapy for Heart Failure at AHA Meeting

11/6/2007 Advanced Cell Technology's Chief Scientific Officer Featured Speaker at American College of Rheumatology/ Association of Rheumatology Health Professionals

11/5/2007 Advanced Cell Technology and the Casey Eye Institute at Oregon Health & Science University Present Results of Functional Studies for RPE Program at Neuroscience 2007

11/2/2007 Advanced Cell Technology Announces Executive Promotions

11/1/2007 Advanced Cell Technology to Present at The Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th

10/31/2007 Advanced Cell Technology's Chief Scientific Officer Delivers Keynote Address at Leading International Stem Cell Conference

10/25/2007 Advanced Cell Presents Phase I (b) Data Demonstrating Safety and Optimal Dosage for Myoblast Program at TCT Conference and Exposition

10/16/2007 ACT's Myoblast Trial Selected as Late Breaking Trial for AHA Conference

10/11/2007 Advanced Cell Technology Announces the Promotion of Dr. Robert Lanza to Chief Scientific Officer

9/24/2007 Advanced Cell Technology Completes Acquisition of Mytogen, Inc.

9/20/2007 NIH Announces Advanced Cell Technology's 'Single Cell Embryo Biopsy Technique' as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding

9/4/2007 Advanced Cell Technology Completes $10 Million Private Placement

8/21/2007 Advanced Cell Technology’s Dr. Robert Lanza Makes List of ''100 Most Inspiring People in the Life-Sciences Industry''

8/2/2007 Advanced Cell Technology Enters Into Definitive Merger Agreement With Mytogen, Inc.

7/2/2007 Advanced Cell Technology Applauds Inclusion of Stem Cell Provision In $152 Billion Federal Funding Measure

6/28/2007 Registration Statement for Equity Related to Advanced Cell Technology’s September 2006 PIPE Becomes Effective

6/21/2007 Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo

6/21/2007 Advanced Cell Technology Announces Critical Advancements in its RPE Program for the Treatment of Macular Degeneration and Other Retinal Degenerative Diseases

6/13/2007 Advanced Cell Technology's VP of Research & Scientific Development, Dr. Robert Lanza, to Deliver Opening Keynote Address at Termis NA 2007 Conference on Regenerative Medicine

6/4/2007 Advanced Cell Technology to Host Conference Call and Webcast to Discuss Recent Developments and Planned Acquisition of Mytogen

5/31/2007 Advanced Cell Technology Enters Into Letter of Intent to Acquire Mytogen, Inc. and Proceed with the Human Clinical Trials Utilizing Myoblasts for the Treatment of Heart Failure

5/9/2007 Advanced Cell Technology’s CEO to Present at Rodman & Renshaw 4th Annual Global Healthcare Conference

5/9/2007 Advanced Cell Technology's Vice President of Research & Scientific Development to Present at the Life Science Institute's Symposium on Wednesday, May 9, 2007

5/7/2007 Precursor Cells Generated From Human Embryonic Stem Cells Show Ability to Repair Vascular Damage in Animals

5/2/2007 Advanced Cell Technology and Wisconsin Alumni Research Foundation Announce Commercial License Agreement

4/27/2007 Advanced Cell Technology’s General Counsel, Jonathan F. Atzen, Interviewed on Bloomberg Television

4/20/2007 Advanced Cell Technology’s Chairman and CEO, William M. Caldwell, IV, to Present at EQUITIES 56th Anniversary Spring Conference 2007

3/23/2007 Advanced Cell’s Michael D. West, Ph.D., To Speak at 3rd Annual Stem Cell Research and Therapeutics Summit on “Strategies for the Accelerated Development of Therapeutics from hES Cells”

3/20/2007 Advanced Cell Technology hESC lines to be used in CIRM-Funded Study To Test Development of New Therapies For Heart Disease

3/12/2007 Advanced Cell Technology Executives to Discuss “The Business of Stem Cells” and Participate in “Conversations with Experts” at The Stem Cell Meeting Hosted by Burrill and Company at UCSF

3/5/2007 Advanced Cell Technology’s Ability to Rescue Vision in Blind Rats Noted in Scientific American

2/28/2007 Advanced Cell Applauds $3 Billion Stem Cell Research Program, Proposition 71, Upheld Monday By A California Appeals Court

2/13/2007 Advanced Cell’s Michael West, Ph.D., Highlights ACTCellerate Platform, A Means of Accelerating the Differentiation of Cells from Human Embryonic Stem Cells, at 2nd Annual Stem Cell Summit

2/12/2007 Advanced Cell Technology Names Noted Biotech Industry Executive Dr. Pedro Huertas, as Chief Development Officer to Manage the Clinical Development and Regulatory Approval Process for its Stem Cell-Based Therapeutic Products

2/8/2007 Advanced Cell Technology Acquires Intellectual Property Assets of Infigen, Inc.

2/6/2007 Advanced Cell Technology Announces Collaboration with the Casey Eye Institute at Oregon Health and Science University

2/2/2007 Advanced Cell Technology Senior Scientist Dr. Robert Lanza Awarded for Outstanding Contributions to Biology by Brown University Biotech Group

1/23/2007 Advanced Cell Technology Engages Burrill & Company to Act as Financial Advisor to Accelerate Formation of New Strategic Partnerships

1/16/2007 Advanced Cell Technology Awarded Federal Grant from National Institutes of Health to Accelerate Embryonic Stem Cell Research

1/11/2007 Advanced Cell Technology CEO Interviewed On CNBC’s “Power Lunch”

1/5/2007 Advanced Cell Technology’s William Caldwell Interviewed By Bloomberg Television

12/14/2006 Advanced Cell Technology Invited to Deliver Keynote Address at Prestigious International Stem Cell Therapy and Regenerative Medicine Conference in London

12/11/2006 Advanced Cell Technology Executives to Present Keynote Address and Company Presentation at New York Society of Security Analysts (NYSSA) Conference

12/7/2006 Advanced Cell Technology’s Robert Lanza, M.D., to Deliver Keynote Address at the University of Florida’s Vision Research Symposium on December 7, 2006

11/9/2006 Advanced Cell Technology Names Current Chief Executive Officer William Caldwell as Chairman of the Board

11/7/2006 Advanced Cell Technology Scientist Dr. Robert Lanza Invited to Address The National Academy of Sciences at Stem Cell Policy Meeting

11/6/2006 Advanced Cell Technology to Present at the 2006 PIPES Conference on November 7th

11/6/2006 Advanced Cell Technology to Present Stem Cell Programs at Rodman & Renshaw’s Annual Healthcare Conference in New York

10/19/2006 Advanced Cell Technology To Present Progress Report on Product Development and ACTCellerate Platform at 2006 BIO Investor Forum

10/16/2006 Advanced Cell Technology’s Dr. Robert Lanza Will Be a Featured Speaker at the 6th Annual Stem Cells & Regenerative Medicine Meeting

9/21/2006 Advanced Cell Technology Reports Visual Function Rescue in Animals Utilizing Human Embryonic Stem Cell-Derived Retinal Cells

9/12/2006 WiCell Research Institute and Advanced Cell Technology Offer to Distribute New Stem Cell Lines to U.S. Researchers

9/6/2006 Advanced Cell Technology’s Dr. Robert Lanza Testifies Before U.S. Senate Subcommittee

9/6/2006 Chairman of Advanced Cell Technology’s Ethics Advisory Board Testifies Before U.S. Senate Subcommittee

9/6/2006 Advanced Cell Technology Announces Settlement of Patent Interference Action

8/23/2006 Advanced Cell Technology Announces Technique to Generate Human Embryonic Stem Cells that Maintains Developmental Potential of Embryo

8/22/2006 Advanced Cell Technology Announces Proposed Financing

7/25/2006 Advanced Cell Technology to Participate at the CIRM’s Roundtable Discussion on Industry & Stem Cells in California

7/21/2006 Advanced Cell Technology Applauds Governor Schwarzenegger for Directing $150 Million Loan to Fund Stem Cell Research

7/19/2006 Advanced Cell Technology Applauds Senate for Bipartisan Support of Stem Cell Legislation; Urges President Bush to fully support embryonic stem cell research

7/17/2006 Advanced Cell Technology Announces Support of Federal Stem Cell Legislation Favorable to the Field of Regenerative Medicine

7/11/2006 Dr. Robert Lanza of Advanced Cell Technology, Inc. and his colleagues receive praise for ''Essentials of Stem Cell Biology'' from The New England Journal of Medicine and Others

6/9/2006 Advanced Cell Technology to Participate at the Marcus Evans ''Facing Stem Cell Research Challenges'' Conference, June 8-9, 2006

6/6/2006 Advanced Cell Technology Unveils ACTCellerate Technology Platform at the European Stem Cells & Regenerative Medicine Congress 2006

5/15/2006 Advanced Cell Technology Announces IND Timetables for Key Therapeutic Programs

5/12/2006 Advanced Cell Technology Announces Cross License of Key Intellectual Property with Kirin

5/11/2006 Advanced Cell Technology to Present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference

5/8/2006 Advanced Cell Technology Announces Formation of Institutional Review Board and Commencement of SCNT Program

4/27/2006 Advanced Cell Technology Announces Collaboration with Xgene Corporation to Assess Its Dermal Cell Technologies in Human Skin Models

4/18/2006 Advanced Cell Technology Announces Completion of Its First GMP Laboratory

4/4/2006 Advanced Cell Technology Announces Exclusive License of Key Intellectual Property Portfolio on Somatic Cell Reprogramming Technology

3/10/2006 Advanced Cell Technology to Participate at The Stem Cell Meeting

3/6/2006 Advanced Cell Technology to Participate in the 1st International Conference on Cell Therapy and Regenerative Medicine

2/28/2006 Advanced Cell Technology Formally Moves Headquarters and Opens Research Facility in California

2/24/2006 Advanced Cell Technology to Participate in Medtech Insight Conference

2/22/2006 Crystal Research Associates, LLC Issues Executive Informational Overview® (EIO®) on Advanced Cell Technology

2/16/2006 Advanced Cell Technology to Participate in the Wharton Health Care Business Conference

2/10/2006 Advanced Cell Technology to Participate in the BIO CEO & Investor Conference 2006

2/9/2006 Leading Stem Cell Company Launches Research Facility in California

1/17/2006 Comprehensive New Book on Stem Cells Co-Edited by Advanced Cell Technology’s Dr. Robert Lanza

12/8/2005 Advanced Cell Technology to Present at the Harris Nesbitt Focus on Healthcare Conference on December 8th

11/23/2005 Scientists Allege U.S. Losing Lead in Stem Cell Research

11/21/2005 Advanced Cell Technology Appoints Two New Members to it's Board of Directors

11/8/2005 Robert Lanza, M.D., to Present at IBC Life Sciences’ Stem Cell Research Challenges Conference

11/7/2005 Advanced Cell Technology’s Chief Scientific Officer Michael West, Ph.D. to be Featured Guest Speaker at Rodman & Renshaw Techvest 7th Annual Healthcare Conference

10/27/2005 Executive Team of Advanced Cell Technology, Inc. to Present 
at the PIPEs Conference 2005 in New York

10/25/2005 Executive Team of Advanced Cell Technology, Inc. to Present at the C.E Unterberg Towbin Life Sciences Conference in New York

10/20/2005 Michael West, PhD, President and Chief Scientific Officer of Advanced Cell Technology, Inc. to Deliver Keynote Address at the University of Toronto’s “Challenges in Regenerative Medicine” Conference

10/16/2005 Advanced Cell Technology Announces Alternative Approach for Derivation
of Embryonic Stem Cell Lines

10/10/2005 C.E. Unterberg Towbin Conference Presentation

9/16/2005 Advanced Cell Technology Raises $17.75 Million through Private Placement of Convertible Notes and Warrants

9/9/2005 Advanced Cell Technology to Deliver the Keynote Address at the Strategies for Engineered Negligible Senescence (SENS) Conference

8/10/2005 Robert Lanza, M.D. to Deliver a Keynote Presentation at the Biotechniques Live! / Drug Discovery Technology & Development World Congress’ Annual Conference

8/5/2005 Advanced Cell Technology Announces New Board Member

7/27/2005 Advanced Cell Technology and The Burnham Institute Announce Collaboration to Isolate Stem Cell-Specific Differentiation Markers

7/12/2005 Dr. Robert Lanza of Advanced Cell Technology Testifies Before Senate Subcommittee

7/11/2005 Dr. Robert Lanza Of Advanced Cell Technology To Testify Before Senate Subcommittee

6/29/2005 Somatic Cell Nuclear Transfer Gives Old Animals Youthful Immune Cells

6/22/2005 A.C.T. Holdings, Inc. Announces Name Change to Advanced Cell Technology, Inc.

6/17/2005 Advanced Cell Technology Expands Senior Scientific Team into California

5/26/2005 Advanced Cell Technology Expands Senior Research Team

5/24/2005 Advanced Cell Technology Reports 2005 First Quarter Results and Highlights Intellectual Property Portfolio

5/19/2005 Advanced Cell Technology Expands Somatic Cell Nuclear Transfer (Cloning) and Cellular Reprogramming Intellectual Property Portfolio

5/4/2005 Michael West, PhD, to Deliver Keynote Address at UC Berkeley’sStem Cells in Regenerative Medicine Conference

4/20/2005 Advanced Cell Technology Names Jonathan F. Atzen as General Counsel

4/18/2005 Advanced Cell Technology Files 8-KA with Securities and Exchange Commission

4/11/2005 Michael West, PhD, to Deliver a Keynote Address at GTCbio Stem Cell Research & Therapeutics Conference

4/4/2005 James Stewart Named Chief Financial Officer at Advanced Cell Technology

3/22/2005 Dr. Robert Lanza of Advanced Cell Technology receives Wired Magazine’s 2005 Rave Award for Medicine

3/8/2005 First Derivation Of Human Embryonic Stem Cells Without Exposure To Cell Feeders